

Resource Summary Report

Generated by SPARC SAWG on Aug 9, 2026

Simcyp

RRID:SCR_003944

Type: Tool

Proper Citation

Simcyp (RRID:SCR_003944)

Resource Information

URL: <http://www.simcyp.com/>

Proper Citation: Simcyp (RRID:SCR_003944)

Description: Research based company providing predictive pharmacokinetic and pharmacodynamic tools, workshops and consultancy services. Their user-friendly simulator and databases predict drug absorption, clearance, distribution and metabolic drug-drug interactions from in vitro data. Simcyp's clients include major global pharmaceutical and bioscience companies, leading academic institutes and regulatory authorities. These clients form the Simcyp Consortium, which together with independent International Scientific Advisory Board, guide scientific development at Simcyp. Simcyp was acquired by Certara in 2012.

Synonyms: Simcyp Ltd, Simcyp Limited

Resource Type: commercial organization

Keywords: modelling, simulation, pharmaceutical, drug development, pharmacokinetics, pharmacodynamics, population, drug-drug interaction, clinical, infant, child, adult, drug, interaction, database, FASEB list

Funding: European Union FP6 ;
UK Department of Trade and Industry

Resource Name: Simcyp

Resource ID: SCR_003944

Alternate IDs: nlx_158337

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260808T185807+0000

Ratings and Alerts

No rating or validation information has been found for Simcyp.

No alerts have been found for Simcyp.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 177 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Reddy MB, et al. (2025) Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. *Clinical pharmacology and therapeutics*, 117(2), 403.

Qian L, et al. (2025) Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta-9-Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes. *Clinical and translational science*, 18(1), e70119.

Li S, et al. (2025) Is the GFR-based scaling approach adequate for predicting pediatric renal clearance of drugs with passive tubular reabsorption? Insights from PBPK modeling. *CPT: pharmacometrics & systems pharmacology*, 14(1), 152.

Jia H, et al. (2025) Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P-Glycoprotein Inhibition. *Clinical pharmacology in drug development*, 14(5), 368.

Huestis MA, et al. (2025) MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis. *CPT: pharmacometrics & systems pharmacology*, 14(2), 376.

Vander Elst Z, et al. (2025) Mathematical Albumin Function for Neonates Undergoing Therapeutic Hypothermia in Comparison with Control Neonates. *Journal of clinical pharmacology*, 65(7), 923.

Alrubia S, et al. (2025) Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption. *British journal of clinical pharmacology*, 91(7), 2028.

Olafuyi O, et al. (2025) Exploring the Impact of Developmental Clearance Saturation on Propylene Glycol Exposure in Adults and Term Neonates Using Physiologically Based Pharmacokinetic Modeling. *Journal of clinical pharmacology*, 65(3), 272.

Burhanuddin K, et al. (2025) Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials. *CPT: pharmacometrics & systems pharmacology*, 14(6), 1050.

Merali S, et al. (2025) Drug-Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model-Based Studies. *Journal of clinical pharmacology*, 65(5), 598.

van Donge T, et al. (2025) Middle-Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib. *CPT: pharmacometrics & systems pharmacology*, 14(6), 1077.

Barry JM, et al. (2025) Prediction of lacosamide concentrations to support dose optimization during pregnancy. *Epilepsia*, 66(2), 346.

Terrier J, et al. (2025) The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID-19 Patients: A Physiologically Based Pharmacokinetic Modeling Study. *Clinical pharmacology and therapeutics*, 117(2), 554.

Ujihira Y, et al. (2025) Genotype, Ethnicity, and Drug-Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin-I Story. *CPT: pharmacometrics & systems pharmacology*, 14(5), 941.

Maruyama T, et al. (2024) Drug-drug interactions between letermovir and tacrolimus in Japanese renal transplant recipients simulated using a physiologically based pharmacokinetic model. *Frontiers in microbiology*, 15, 1480874.

Tsuchitani T, et al. (2024) Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model. *CPT: pharmacometrics & systems pharmacology*, 13(7), 1224.

Okudaira N, et al. (2024) Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients. *CPT: pharmacometrics & systems pharmacology*, 13(8), 1366.

Pippa LF, et al. (2024) Impact of obesity and roux-en-Y gastric bypass on the pharmacokinetics of (R)- and (S)-omeprazole and intragastric pH. *CPT: pharmacometrics & systems pharmacology*, 13(9), 1528.

Mostafa S, et al. (2024) Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. *CPT: pharmacometrics & systems pharmacology*, 13(3), 424.

Shuklinova O, et al. (2024) Can 3D Printed Tablets Be Bioequivalent and How to Test It: A PBPK Model Based Virtual Bioequivalence Study for Ropinirole Modified Release Tablets. *Pharmaceutics*, 16(2).